Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

METAFIGHT · Understanding and fighting metastasis via dissection of the Core Invasive Machinery

FP7Status: CLOSED1 January 200831 December 2010EU funding €2,999,609

The co-operative Metafight project will perform functional studies to understand the dissemination and outgrowth of metastasis through systematic analysis of the Core Invasive Machinery contained within integrin-mediated ECM attachment structure. It includes a large and discretely localised intracellular signalling network which drives migration and invasion. Our strategy is based on the hypothesis that metastatic cells arise from molecular changes that alter the primary tumour architecture as well as the tumor microenvironment, by reversible modulation of cell adhesion, onset of signalling pathways and acquisition of novel migratory and invasive capacities. The Metafight Consortium is strengthened by established combined expertise on adhesion receptor signalling and availability of unique tumor cell and cancer animal model systems. We will characterise known and novel components of the Core Invasive Machinery, responsible for development and homing of metastasis, by innovative in vivo non-invasive imaging techniques. The Metafight project comprises seven major interrelated Work Packages (WP). WP1 is designed to investigate the molecular and functional architecture of the Core Invasive Machinery, from which depends tumour cell migration and eventually invasion. WP2 and WP3 screen for key modulators of metastasis formation in in vivo murine models, by non-invasive imaging techniques. WP4 is related to a comprehensive proteomic analysis of expression and phosphorylation of our candidate modulators in metastasis formation. WP1-4 feed into WP5, which builds upon and exploits knowledge generated in the first four WPs and translates it into existing pharmacological interventions to generate new candidate drugs. This will lead to patent filing and licensing strategies. WP6 and WP7 handle dissemination and management activities. The ultimate accomplishment will include improvement of health, reduction of health expenses, as well as creation of new jobs and economic benefit.

Consortium · 10 organisations

coordinator

UNIVERSITA DEGLI STUDI DI TORINO

IT · €465,400

participant

UNIVERSITEIT LEIDEN

NL · €386,488

participant

ACTAR AB

SE · €201,000

participant

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

ES · €280,499

participant

PHARMA MAR SA

ES · €154,234

participant

ARTTIC

FR · €211,680

participant

KAROLINSKA INSTITUTET

SE · €325,710

participant

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

DE · €489,562

participant

FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA

ES · €276,900

participant

TURUN YLIOPISTO

FI · €208,136

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.